Related Experiment Video
Updated: Feb 25, 2026
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay
Jamie Feng1, Sameena Khan1, Thomas Waddell2
1Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Introduction:
Circulating tumor DNA (ctDNA) has emerged as an important prognostic factor in patients with cancer. Management of early stage NSCLC remains challenging with a high rate of disease recurrence.
Methods:
In this prospective cohort, 153 patients with clinical stage I NSCLC (75.8% pathologic stage I) underwent real-time plasma ctDNA testing using a tumor-informed whole exome sequencing approach, RaDaR.
Results:
Preoperative ctDNA was detected in 22.4% of patients (6 wk of median turnaround time) and was significantly associated with recurrence-free survival (RFS) (hazard ratio: 3.81, p = 0.006). No patients with pathologic stage I disease had detectable postoperative ctDNA. The 2-year RFS was 84.2%, with inferior outcomes among patients with preoperative ctDNA detected (69.1%). In pathologic stage I NSCLC, preoperative ctDNA detection and invasive tumor size remained independently associated with RFS.
Conclusion:
Here, we demonstrate the clinical feasibility of plasma ctDNA to inform treatment decision-making in stage I NSCLC.
Clinicaltrials:
gov identifier: NCT05254782.
More Related Videos
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019